Pro 2013-015 (Notice of Jianfeng Group's 2012 Annual General Meeting of Shareholders)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2013-015
Zhejiang Jianfeng Group Co., Ltd.
Notice on Convening 2012 Annual General Meeting
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Tips: Does
l Provide Online Voting: No
, Basic Information on Convening Meeting
Session of (I) Shareholders' Meeting: Convener of 2012 Shareholders' Meeting
(II) Shareholders' Meeting: the date and time of the (III) meeting of the board of directors of the company
: 9:00 a.m. on may 31, 2013.
(IV) meeting voting method: on-site voting method.
(V) Meeting Place: Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
2. Meeting Deliberated Matters
1, Deliberated the Work Report of the Board of Directors in 2012;
2, review the work report of the board of supervisors in 2012;
3, review the 2012 financial final accounts report;
4, review the 2012 profit distribution plan;
5, Deliberating the Proposal of Hiring 2013 Audit Institutions;
6, Deliberating the Proposal of Providing Guarantee for Holding Subsidiaries;
7, Deliberating the Proposal of Mutual Guarantee with Zhejiang Kane Special Materials Co., Ltd.;
8, Review the 2012 Annual Report and Its Summary; the
meeting will also hear the 2012 debriefing report of independent directors of the company.
3. Meeting Attendees
1. All shareholders of the company registered in Shanghai Branch of China Securities Central Depository and Clearing Corporation after the end of the transaction on May 28, 2013 (equity registration date) And their authorized principals can attend.
2, Directors, Supervisors and Senior Management of the Company.
Measures for Registration of 4. Meetings
1, Certificate of Holder, Power of Attorney of Legal Representative and ID Card Registration of Attendants; Shareholders of public shares shall register with their shareholder account cards and their identity cards. Shareholders can pre-register by letter or fax.
2. Pre-registration time: May 30, 2013.
. Place of registration: Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
Other 5. Matters
1, Meeting Contact Information
Contact Address: Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
telephone number: 0579-82324699
fax number: 0579-82324699
2. The meeting will last for half a day, and the participating shareholders will take care of their own transportation and accommodation.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 23, 2013
Annex 1: form of Power of Attorney
Power of Attorney
Zhejiang Jianfeng Group Co., Ltd.:
hereby entrusts Mr. (Madam) to attend the 12-year annual shareholders' meeting of your company's 20 held on May 31, 2013 on behalf of the unit (or myself) and exercise voting rights on his behalf.
Principal Signature (Seal): Trustee Signature:
Principal Identity Card Number: Trustee Identity Card Number:
Principal Holds Number: Principal Shareholder Account Number:
Date of Entrustment: May
Serial Number |
Proposal Content |
Agree |
Oppose |
Abstention |
1 |
2012 Board of Directors Work Report |
|||
2 |
2012 Board of Supervisors Work Report |
|||
3 |
2012 Annual Financial Statement |
|||
4 |
2012 Profit Distribution Plan |
|||
5 |
# Proposal 314 Hiring 2013 Audit Institution |
|||
6 |
Proposal to Provide Guarantee for Holding Subsidiaries |
|||
7 |
and Zhejiang Kane Special Materials Co., Ltd. Proposal of Mutual Guarantee |
|||
8 |
2012 Annual Report and Its Summary |
Remarks:
The principal shall choose one of the intentions of "agree", "oppose" or "abstain" in the power of attorney and tick "√". If the principal does not give specific instructions in this power of attorney, the trustee The right to vote according to his own wishes.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page